Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Int J Oncol. 2013 Apr;42(4):1212-8. doi: 10.3892/ijo.2013.1799. Epub 2013 Jan 25.
The global incidence of colorectal cancer (CRC) is increasing. Although there are emerging epigenetic factors that contribute to the occurrence, development and metastasis of CRC, the biological significance of epigenetic molecular regulation in different subpopulations such as cancer stem cells remains to be elucidated. In this study, we investigated the functional roles of the H3K4 demethylase, jumonji, AT rich interactive domain 1B (JARID1B), an epigenetic factor required for the continuous cell growth of melanomas, in CRC. We found that CD44(+)/aldehyde dehydrogenase (ALDH)(+) slowly proliferating immature CRC stem cell populations expressed relatively low levels of JARID1B and the differentiation marker, CD20, as well as relatively high levels of the tumor suppressor, p16/INK4A. Of note, lentiviral‑mediated continuous JARID1B depletion resulted in the loss of epithelial differentiation and suppressed CRC cell growth, which was associated with the induction of phosphorylation by the c‑Jun N‑terminal kinase (Jnk/Sapk) and senescence‑associated β‑galactosidase activity. Moreover, green fluorescent‑labeled cell tracking indicated that JARID1B‑positive CRC cells had greater tumorigenicity than JARID1B‑negative CRC cells after their subcutaneous inoculation into immunodeficient mice, although JARID1B‑negative CRC cells resumed normal growth after a month, suggesting that continuous JARID1B inhibition is necessary for tumor eradication. Thus, JARID1B plays a role in CRC maintenance. JARID1B may be a novel molecular target for therapy‑resistant cancer cells by the induction of cellular senescence.
全球结直肠癌(CRC)的发病率正在上升。尽管有新兴的表观遗传因素有助于 CRC 的发生、发展和转移,但在癌症干细胞等不同亚群中,表观遗传分子调控的生物学意义仍有待阐明。在这项研究中,我们研究了组蛋白 H3K4 去甲基酶 jumonji、富含 AT 的相互作用域 1B(JARID1B)在 CRC 中的功能作用,JARID1B 是黑色素瘤细胞持续生长所必需的表观遗传因子。我们发现 CD44(+)/乙醛脱氢酶(ALDH)(+)增殖缓慢的不成熟 CRC 干细胞群体表达相对较低水平的 JARID1B 和分化标志物 CD20,以及相对高水平的肿瘤抑制因子 p16/INK4A。值得注意的是,慢病毒介导的连续 JARID1B 耗竭导致上皮分化丧失,并抑制 CRC 细胞生长,这与 c-Jun N-末端激酶(Jnk/Sapk)的磷酸化诱导和衰老相关的β-半乳糖苷酶活性有关。此外,绿色荧光标记的细胞追踪表明,JARID1B 阳性 CRC 细胞比 JARID1B 阴性 CRC 细胞具有更强的致瘤性,在将其皮下接种到免疫缺陷小鼠后,尽管 JARID1B 阴性 CRC 细胞在一个月后恢复正常生长,但这表明持续抑制 JARID1B 是肿瘤根除所必需的。因此,JARID1B 在 CRC 维持中发挥作用。通过诱导细胞衰老,JARID1B 可能成为治疗耐药癌细胞的新分子靶点。